Koyfin Home > Directory > Health Care > Aerie Pharmaceuticals > Preferred Equity

Aerie Pharmaceuticals Preferred Equity Chart (AERI)

Aerie Pharmaceuticals annual/quarterly Preferred Equity from 2012 to 2013.
  • Aerie Pharmaceuticals Preferred Equity for the quarter ending September 09, 2013 was $73m a 15.59% increase of 11m year over year
  • Aerie Pharmaceuticals Preferred Equity for the last 12 months ending September 09, 2013 was $73m a 15.59% increase of 11m year over year
  • Aerie Pharmaceuticals Annual Preferred Equity for 2012 was $63m a 3.01% increase of 2m from 2011
  • Aerie Pharmaceuticals Annual Preferred Equity for 2011 was $61m
Other Balance Sheet Metrics:
  • Aerie Pharmaceuticals Total Assets for the quarter ending September 09, 2018 was $309m a 6.12% increase of 19m year over year
  • Aerie Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $6m a 11.47% increase of 1m year over year
  • Aerie Pharmaceuticals Total Equity for the quarter ending September 09, 2018 was $269m a 49.51% increase of 133m year over year
View Chart On Koyfin

Quarterly AERI Preferred Equity Data

09/2013$73m
03/2013$63m
12/2012$63m
03/2012$61m

Annual AERI Preferred Equity Data

2012$63m
2011$61m